-
-
-
-
-
-
-
Palisade Bio's (PALI) Lead Product Candidate PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory LPS
-
-
-
-
-
-
-
Intra-Cellular Therapies (ITCI) to Resume Trading at 7:30 a.m.
-
-
-
-
-
-
-
Galectin Therapeutics (GALT) Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertensi
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease
-
-
-
-
-
-
-
Roche falls, Argenx (ARGX) gains after Chugai's Enspryng drug for myasthenia gravis fails
-
-
-
-
-
-
-
Geron Corp (GERN) Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat
-
-
-
-
-
-
-
Nurix Therapeutics (NRIX) Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
-
5,513 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving Hot FDA News reports.